CPIX — Cumberland Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $21.00m
- $18.24m
- $39.55m
- 64
- 83
- 46
- 69
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 34.4 | 37.4 | 36 | 42 | 39.6 |
Cost of Revenue | |||||
Gross Profit | 27 | 29 | 28.6 | 33.4 | 33.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 43.7 | 43.8 | 43.7 | 47.7 | 49.1 |
Operating Profit | -9.29 | -6.38 | -7.68 | -5.7 | -9.55 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.29 | -6.57 | -5.56 | -5.58 | -6.29 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.21 | -6.63 | -5.6 | -5.65 | -6.33 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -3.54 | -3.34 | -3.51 | -5.57 | -6.28 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.54 | -3.34 | -3.51 | -5.57 | -6.28 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.598 | -0.423 | -0.308 | -0.36 | -0.287 |